Coherus BioSciences 미래 성장

Future 기준 확인 1/6

Coherus BioSciences 의 수익은 연간 90.4% 감소할 것으로 예상되는 반면, 연간 수익은 5.8% 로 증가할 것으로 예상됩니다. 5.8% 연간. EPS는 연간 50.9% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 42.6% 로 예상됩니다.

주요 정보

-90.4%

수익 성장률

-50.9%

EPS 성장률

Biotechs 수익 성장	27.5%
매출 성장률	5.8%
향후 자기자본 수익률	42.6%
애널리스트 커버리지	Good
마지막 업데이트	16 Dec 2024

최근 미래 성장 업데이트

Recent updates

There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise

Dec 21

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 16

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Nov 06

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Sep 22

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Aug 07

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

수익 및 매출 성장 예측

NasdaqGM:CHRS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	318	-45	-73	-82	5
12/31/2025	279	-71	-34	-38	5
12/31/2024	256	10	-64	-87	7
9/30/2024	304	0	-63	-62	N/A
6/30/2024	308	-29	-56	-54	N/A
3/31/2024	302	-59	-154	-153	N/A
12/31/2023	257	-238	-176	-175	N/A
9/30/2023	211	-217	-229	-262	N/A
6/30/2023	182	-264	-213	-245	N/A
3/31/2023	183	-271	-225	-256	N/A
12/31/2022	211	-292	-246	-241	N/A
9/30/2022	239	-279	-231	-193	N/A
6/30/2022	276	-230	-180	-143	N/A
3/31/2022	304	-210	-121	-93	N/A
12/31/2021	327	-287	-39	-37	N/A
9/30/2021	364	-232	-90	48	N/A
6/30/2021	395	-165	-60	82	N/A
3/31/2021	443	-76	-16	142	N/A
12/31/2020	476	132	139	154	N/A
9/30/2020	489	162	113	139	N/A
6/30/2020	487	181	125	146	N/A
3/31/2020	435	145	84	99	N/A
12/31/2019	356	90	15	28	N/A
9/30/2019	232	-12	-38	-37	N/A
6/30/2019	121	-118	-136	-134	N/A
3/31/2019	37	-185	-184	-183	N/A
12/31/2018	N/A	-209	-160	-159	N/A
9/30/2018	N/A	-196	-143	-142	N/A
6/30/2018	N/A	-196	N/A	-141	N/A
3/31/2018	1	-208	N/A	-161	N/A
12/31/2017	2	-238	N/A	-200	N/A
9/30/2017	2	-265	N/A	-257	N/A
6/30/2017	165	-122	N/A	-278	N/A
3/31/2017	178	-137	N/A	-250	N/A
12/31/2016	190	-127	N/A	-253	N/A
9/30/2016	199	-104	N/A	-160	N/A
6/30/2016	44	-259	N/A	-158	N/A
3/31/2016	37	-248	N/A	-151	N/A
12/31/2015	30	-223	N/A	-108	N/A
9/30/2015	26	-200	N/A	-147	N/A
6/30/2015	35	-137	N/A	-92	N/A
3/31/2015	33	-103	N/A	-72	N/A
12/31/2014	31	-87	N/A	-24	N/A
9/30/2014	26	-73	N/A	14	N/A
6/30/2014	10	-86	N/A	41	N/A
3/31/2014	6	-70	N/A	37	N/A
12/31/2013	3	-54	N/A	15	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CHRS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CHRS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CHRS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CHRS 의 수익(연간 5.8% ) US 시장( 9.1% 보다 느리게 성장할 것으로 예상됩니다. 9.1% 연간).

고성장 수익: CHRS 의 수익(연간 5.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CHRS 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 42.6 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/20 10:52
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Coherus BioSciences, Inc. 17 애널리스트 중 7 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Colleen Kusy	Baird
Balaji Prasad	Barclays
Balaji Prasad	Barclays

Coherus BioSciences 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.55 loss, revenue downgraded

Forecast breakeven date pushed back to 2026

Consensus revenue estimates fall by 12%

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Recent updates

There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carinoma at ASCO-GI 2025

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Intas Pharmaceuticals Limited entered into asset purchase agreement to acquire UDENYCA Franchise of Coherus BioSciences, Inc. (NasdaqGM:CHRS) for $560 million.

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Coherus BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Coherus BioSciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Forecast breakeven date moved forward to 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Coherus BioSciences, Inc. announced that it has received $38.7 million in funding

Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer

Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting

Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$0.55 loss, revenue downgraded

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Forecast breakeven date pushed back to 2026

Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New major risk - Financial position

Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Lead Independent Director exercised options to buy US$139k worth of stock.

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer

Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023

Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Chairman notifies of intention to sell stock

Consensus revenue estimates fall by 12%

New major risk - Share price stability

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.3% to US$12.88

Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Price target decreased by 7.6% to US$12.11

Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors

Coherus Launches Yusimry™, A Biosimilar of Humira®

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Price target decreased by 12% to US$13.63

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Price target decreased by 13% to US$15.56

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Consensus revenue estimates fall by 13%

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.09 loss